MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
Emergent BioSolutions Inc (NYSE: EBS)*
Organization & Developments: Emergent Biosolutions
Parents
Emergent BioSolutions Inc (NYSE: EBS)*
Children
*Biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics
*BioThrax
*Delivered 4,000,000 doses of BioThrax vaccine to HHS under a $120 million contract for 5,000,000 doses
*DEVELOPS VACCINES AND THERAPEUTICS FOR BIODEFENSE AGAINST BIOLOGICAL AGENTSTHAT ARE POTENTIAL WEAPONS OF BIOTERRORISM AND BIOWARFARE
*EBS, Emergent Biosolutions
*Emergent Biodefense Operations Lansing LLC
*Emergent BioSolutions is focused on the development, manufacture, and commercialization of vaccines and antibody therapeutics for infectious diseases.
*Immunobiotics are pharmaceutical products, such as vaccines and immune globulins, that induce or assist the body’s immune system
*In biodefense business, develop and commercialize immunobiotics for use against biological agents that are potential weapons of
*In commercial business, develop immunobiotics for use against infectious diseases with significant unmet or underserved medical
*Lobbying effort has cost more than $1 million since 2005
2012: Emergent BioSolutions to develop HHS innovation center (2012)
2013: Why Emergent BioSolutions Paid $26 Million for Anti-Chem Lotion From Bracco Diagnostics Inc. (2013)
2014: Emergent BioSolutions Receives Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease
2014: For Emergent BioSolutions, Anthrax vaccine remains the cash cow
2015: Emergent BioSolutions wins $20 million contract to produce Ebola treatment_modernhealthcare
2016: Anthrax Vaccine Maker Emergent Hopes To Profit From Biotech Spinoff
2016: Emergent Bio nabs BioThrax contract valued up to $911M; 2016 guidance updated; shares up 20% - Emergent BioSolutions Inc. (NYSE:EBS)
2016: Emergent BioSolutions Stock Plunges On Light Anthrax Vaccine Order
2016: Ligand Pharma Adds Tech, Grows On Partners’ Success
2017: Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure
2017: Emergent BioSolutions opens expanded East Baltimore vaccine plant
2019: Emergent Biosolutions: Leader In The Public Health Threats Space_seekingalpha.com
2019: USAMRDC_U.S. Army Medical Research Acquisition Activity awards $25M contract for regulatory, nonclinical, clinical, and program management support
2020: Emergent BioSolution's deal with Johnson & Johnson has geopolitical significance
2020: Emergent BioSolutions, BARDA reach $628M deal to manufacture COVID-19 vaccine hopefuls
2020: Emergent BioSolutions: Revising My Valuation
2021: BARDA, Emergent BioSolutions break off $600M Covid-19 vaccine manufacturing deal
2022: Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments_ seekingalpha.com
2022: Emergent scores a DoD award to evaluate its chikungunya vaccine in the field
2023: BARDA awards Emergent 10-year, $704M contract for Ebola treatment
2023: Emergent BioSolutions to reduce workforce by about 5%_reuters
2023: Emergent BioSolutions: A Turnaround In Sight With OTC Narcan Amidst Ongoing Opioid Crisis_ seekingalpha
2023: Emergent to lay off 400 staffers, eliminate executive position in pivot away from contract manufacturing_fiercepharma
2024: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
2024: Emergent BioSolutions Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Emergent BioSolutions to cut 300 employees, shutter 2 facilities in restructuring launched under new CEO
2024: Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
2024: Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario
2024: New CEO Appointment A Clear Positive For Emergent BioSolutions
2024: SIGA Technologies Vs. Emergent BioSolutions: Product Portfolio And Future Outlook
2024: U.S. Army_Emergent Biodefense Operations Lansing LLC, Lansing, Michigan, was awarded a $235,800,000 firm-fixed-price contract for BioThrax anthrax vaccines.
Jumps
*Key People: Emergent Biosolutions
Finance & Acquisitions: Emergent Biosolutions